Table 2 Frequency of the metabolic syndrome criteria in patients with SLE and controls*.
| Patients with SLE | Controls | p Value | |
|---|---|---|---|
| NCEP definition | |||
| Waist girth (%) | 48.0 | 33.7 | 0.05 |
| Hypertension† (%) | 51.0 | 34.7 | 0.02 |
| Hypertriglyceridaemia (%) | 27.5 | 16.8 | 0.09 |
| Low HDL (%) | 52.0 | 58.4 | 0.40 |
| Hyperglycaemia (%) | 2.9 | 2.0 | 1.00 |
| Total meeting definition (%) | 29.4 | 19.8 | 0.14 |
| WHO definition | |||
| Insulin resistance‡ (%) | 44.1 | 24.8 | 0.005 |
| Dyslipidaemia (%) | 51.0 | 41.6 | 0.21 |
| Hypertension† (%) | 43.1 | 20.8 | <0.001 |
| Central obesity (%) | 51.0 | 35.6 | 0.03 |
| Total meeting definition (%) | 32.4 | 10.9 | <0.001 |
HDL, high‐density lipoprotein; NCEP, National Cholesterol Education Program Adult Treatment Panel III; SLE, systemic lupus erythematosus; WHO, World Health Organization.
*p Values were calculated using Fisher's exact test.
†Hypertension is defined as ⩾130/85 mm Hg or use of drugs for blood pressure in the NCEP criteria and ⩾140/90 mm Hg or use of drugs for blood pressure in the WHO criteria.
‡Insulin resistance defined by the presence of any of the following three criteria: a homeostasis model assessment index (fasting glucose (mmol/l)×fasting insulin (μU/ml)/22.5 in the top quartile of a population without diabetes (>2.114 in the Study of Inherited Risk of Coronary Atherosclerosis sample), impaired fasting glucose (⩾110 mg/dl) or diabetes.